The US FDA has approved 3 NDAs and 2 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 5 novel products in 2022
In Jan 2022, the major highlights were Quviviq's approval for insomnia, Cibinqo for atopic dermatitis, Kimmtrak for unresectable or metastatic…
